Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02,...
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and...
BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics to Participate in the 6th Annual Biotechnology Conference
BRISBANE, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Vera), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
Vera Announces Pricing of Upsized Public Offering of Class A Common Stock
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
“ Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment “ Placebo cohort...
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...